Resumen

MARTI CARRERA, E. et al. The sentinel lymph node biopsy for melanoma: our experience. Cir. plást. iberolatinoam. [online]. 2006, vol.32, n.2, pp.117-126. ISSN 1989-2055.

The sentinel lymph node biopsy (SLNB) has recently been accepted as one of the most important prognostic factors of the cutaneous primary melanoma by the AJCC (American Joint Committee on Cancer), even its overall use is still not extended to all the melanoma units and there are many controversies about its use. Among other aspects, there is no consensus about if the previous wide local excision can alter the results of the biopsy. This is a retrospective study done over 78 consecutive cases of SLNB for melanoma between May´99 and Jan´04. All of them were remitted from Dermatology with the diagnose of melanoma, tumor thickness >1.0mm and no clinical nodes (AJCC est. I and II). Out of the 78 cases, 42 were women and 36 men, with an average age of 53.5. The average Breslow thickness was of 2.78mm. The wide local excision(WLE) was done by Dermatology at a previous time in 59 cases (76.62%), while 18 patients had the WLE at the time of the SLNB. The delay between the WLE and the SLNB was of 5.87 months. In the 19.23% (15patients) the SLNB was not feasible because there was not found colloid captation by any node; 12 of them had de WLE previous to the SLNB, with a delay of 5.06months; 50% (39) of the nodes were negative for melanoma cells; 25.74% (20patients) were positive. The follow up time was of 23.12months; 18 patients presented metastasis or died, while 47 cases (60%) are actually free of disease. We corroborate that the SLNB is a low morbility technique with an important staging function for the primary cutaneous melanoma. We don´t find any difference in the survival of patients with previous WLE compared with those whom the WLE was done concurrently.

Palabras clave : Melanoma; Sentinel limph node.

        · resumen en Español     · texto en Español     · Español ( pdf )